Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Retatrutide appears to have a similar safety profile to other GLP-1 medications: No increased risk of pancreatitis in trials so far No hepatotoxicity signals (liver damage) No cases of ketoacidosis Serious adverse events were rare (2.5% of participants) The trials are ongoing, so we'll learn more about long-term safety
Cuando es administrada crnicamente el efecto incretnico se caracteriza por aumento de los niveles de RNAm de insulina31 y de los niveles de los factores de transcripcin de RNAm de insulina
Adults with obesity (BMI 30 ) or overweight (BMI 27 ) with at least one weight-related condition like type 2 diabetes, high blood pressure, or sleep apnea
One STEP trial showed an average loss of about 10% with Wegovy versus 3% with placebo over 68 weeks
Yang F et al
Baaran et al
